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A polyurethane intraurethral catheter (IUC) was used in 27 patients with benign prostatic hypertro-
phy who were unfit for surgery, or were awaiting surgery. All of them had previously had a peri-
urethral catheter inserted. The IUC was inserted with a cystoscope under fluoroscopic control.
Spontaneous voiding through the IUC resumed in 25 patients (93%) in the immediate postprocedure
period. At the end of 6 months follow-up, the peak flow rates and the residual volumes estimated in
22 patients were satisfactory. Immediate complications included incontinence due to distal dis-
placement in 2 patients and hematuria in one patient; long-term complications included mild en-
crustation ofthe IUC in 2 patients and calculus formation on the IUC in patient. None of the patients
had clinically significant urinary tract infection. The presence of the IUC did not compromise the
subsequent transurethral resection of the prostate gland. We recommend the use of an IUC for up to
6 months in patients with urinary retention who are awaiting surgery or are unfit for surgery as an
alternative to an indwelling urethral catheter.
KEY WORDS: Prostate, stents, urethral catheter, urinary retention, prostatic hyperplasia, bladder neck
obstruction, prostatic hypertrophy
INTRODUCTION
Retention of urine is one of the common clinical presen-
tations of benign prostatic hypertrophy (BPH). For
decades this was managed with an indwelling urethral
catheter. In many instances the indwelling urethral
catheter has to be left in place for an extended period of
time either because the patient is unfit for surgery, or be-
cause his condition requires that surgery be postponed.
Also, in many centers, there is a waiting list of patients
for prostatectomy, and the urethral catheter remains in-
dwelling for weeks or even months.
An indwelling catheter is a common cause of urinary
tract infections and urethral stricture and is associatedwith
nearly a 3-fold increase in mortality among hospitalized
patients (1,2). Men with indwelling catheters have low
self-esteem, are unable to perform sexually, and have dif-
ficulty in discharging their day-to-day activities.
The polyurethane double Malecot intraurethral catheter
(IUC) is a simple physiological prosthesis that obviates
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many of the difficulties faced with an indwelling intrau-
rethral catheter (3). We present here our study of 27 pa-
tients in whom urinary retention caused by BPH was
managed with an IUC.
113
MATERIALS AND METHODS
Twenty-seven patients with retention of urine caused by
BPH were offered the IUC as an alternative treatment in-
stead of an indwelling urethral catheter. These patients
were either at high risk for complications of anesthesia (n
22) or had a potentially long waiting period for prosta-
tectomy (n 5). In a institution like ours serving a large
segment of the population, the waiting period for
transurethral resection of the prostate or prostatectomy
often extends up to 6 to 8 months. Preprocedural assesse-
ment included subjective evaluation of bladder outflow
obstruction, physical examination, cystourethroscopy,
and subjective evaluation of sexual function.
A 16 F polyurethane double Malecot type ofIUC man-
ufactured by Angiomed was used. It is available in 35- to
70-mm lengths. It consists of a crown, the proximal bas-114 S. PUNEKAR et al.
ket, and a distal basket (Fig. 1). A nonabsorbable
(nylon/silk) 0.20-mm suture is connected to the distal end
of the IUC.
The procedure was carried out under local anesthesia (in-
stallation ofLignocainejelly) on the uroradiology table. The
length of the prostatic urethra was determined by prelimi-
nary cystourethroscopy. The IUC was placed in the distal
endofa 23.5 cystoscope sheathand introduced into the blad-
der (Fig. 2). The IUC was expelled into the bladder with the
use of the obturator. Under fluoroscopic control, the IUC
was placed in the prostatic urethra with the distal end of the
IUC positioned just beyond the verumontanum by pulling
the nylon string attached to it (Fig. 2). The position was con-
firmed by cystoscopy and fluoroscopy. The nylon thread
was kept long for 24 hours. Postprocedural micturition was
closely observed immediately after treatment, and the pa-
tients were discharged from the hospital after 24 hours. All
patients were given cotrimoxazole for 7 days. In the 2 ini-
tial patients we performed cystourethrography to confirm
the position of the IUC (Fig. 3).
Follow-up visits were scheduled at 1, 3, and 6 months
postoperatively. Postoperative assessement included eval-
Figure 2 The instrumentation set.
\
Figure The intraurethral catheter. Figure 3 The intraurethral catheter in situ.IUC FOR URINARY RETENTION IN BPH 115
uation of subjective symptoms, uroflowmetry, measure-
ment of residual volume, and subjective evaluation ofsex-
ual function. Urine cultures were taken weekly during the
first 2 weeks. At the end of 6 months 5 patients were lost
to follow-up. Of the remaining 22 patients, 17 were sub-
jected to transurethral resection of the prostate. Four pa-
tients refused further therapy; one died of cardiac illness.
RESULTS
At the preoperative cystoscopic examination 22 patients
(81%) had predominantly lateral lobe hyperplasia while 5
patients (19%) had median lobe hyperplasia. In addition,
patient had a previous undetected small vesical calcu-
lus, which was removed before the IUC was implanted.
Before the episode of urinary retention 4 patients (15%)
reported normal erection and antegrade ejaculation.
Spontaneous voiding was reestablished in 25 patients
(93%) while the other 2 patients in whom the IUC had
slipped into the bladder developed urinary retention. After
repositioning of the IUC these 2 patients also had satis-
factory voiding. The urinary flow parameters reported in
Table show satisfactory mean peak flow rates and mean
residual volumes, which were maintained up to the last
follow-up.
Six patients (22%) developed urinary frequency, which
resolved on its own over a period of 2 to 3 weeks. None
of the patients in whom the IUC was retained developed
clinically significant urinary tract infections. During the
follow-up period, 5 patients (19%) had an asymptomatic
urinary tract infection with Proteus. Appropriate antibi-
otics were administered.
Four of our patients who were sexually active before
development of retention of urine reported resumption of
normal sexual activities after placement of the IUC.
However, all of them reported retrograde ejaculation.
Immediate complications occurred in 3 patients (11%).
These included incontinence secondary to the slipping of
the IUC below the verumontanum in 2 patients and hema-
turia in another patient. Continence was regained after
repositioning of the IUC, while hematuria resolved spon-
taneously within 24 hours. Long-term complications (i.e.,
at end of 6 months) occurred in 3 patients (11%). These
included mild encrustation ofthe IUC in 2 patients and se-
vere encrustation leading to calculus formation on the IUC
in patient (Fig. 4). The severely encrusted IUC had to be
removed surgically through the suprapubic route, because
the IUC had slipped into the bladder, and the patient had
not come for follow-up for more than 8 months.
At the end of 6 months, 5 patients were lost to follow-
up. Of the remaining 22 patients, 17 patients were sub-
jected to transurethral resection ofthe prostate. At the time
of transurethral resection there was mild cystitis in 3 pa-
tients and congestion of the prostate in 2 patients. The
transurethral resections were unremarkable.
DISCUSSION
The definitive surgery of many patients with retention of
urine caused by BPH is often delayed for several weeks
oreven months because the patients may be suffering from
concurrent severe medical illness that preclude anesthesia
or there may be a long waiting period before surgery.
Insertion of a urethral catheter is the simplest form of
urinary diversion, which is commonly used in such a clin-
ical setting. However, prolonged catheterization is associ-
ated with anumber ofcomplications such as urosepsis and
urethral stricture formation (4). Alteration in body image
with associated depression and the discomfort related to
the catheter are other factors that complicate indwelling
urethral catheterization (5). Thus, an alternative modality
for the management of urinary retention caused by an en-
larged prostate, which permits a catheter-free existence,
would be a valuable addition in the therapeutic armamen-
tarium of the urologist.
In 1980, Fabian (6) pioneered the use ofan intraurethral
stent in the management of bladder outflow obstructions.
This was a steel spiral placed in the prostatic urethra with
an anchoring tail in the bulbar urethra. Subsequently
Nissenkorn and Richter (3) reported the use of the double
Malecot type IUC made of polyurethane, with excellent
results. In 1992 we began to use this type of catheter.
Attractive features of the IUC are its simple design, ease
of insertion, positioning within the urethra under direct vi-
sion, and relatively inexpensive cost. The procedure can
be performed under local anesthesia without supplemen-
Table Pre-and Postoperative Urinary Flow Parameters (Means + SD)
Follow-up
Preoperative mo 3 no 6 mo
No. of patients assessed 27 18 8 6
Peak flow rate (ml/s) 15.1 + 4.2 13.6 + 3.4 13.2 + 3.6
Voided volume (ml) 196 + 80 204 + 71 202 + 82
Residual volume (ml) 43 + 64 40 + 58 33 + 62116 S. PUNEKAR et aL
Figure 4 Voiding cystourethrogram with the IUC in place.
Figure 5 Calculus formation on the IUC.
tal intravenous sedation and analgesia. The operative time
is only 20 to 30 minutues.
The therapeutic benefits of an IUC are apparent. The
majority of patients void satisfactorily without the need
for external tubing or drainage. In our study 93% of the
patients could void spontaneously after placement of an
IUC. Satisfactory mean peak flow rates were obtained in
all patients and the improvement seen from the first fol-
low-up was maintained until the 6th month follow-up.
Mean residual urine volume remained low at both the
short- and long-term follow-ups.
Because patients are catheter-free, their day-to-day ac-
tivities as well as social lives are not affected. This is par-
ticularly significant in the context of a conservative social
milieu such as that in Indian, wherein a patient with an in-
dwelling urethral catheter could be a social outcast.
The IUC does not hinder routine sexual activity in these
patients. All of our patients who were sexually active be-
fore the insertion of the IUC continued to remain so even
after its insertion, although in all of them retrograde ejac-
ulation persisted. A major European multicenter study re-
cently reported major positive effects on sexual function
after prostatic stent placement (7). In their study, patients
who reported antegrade ejaculation preoperatively con-
tinued to have antegrade ejaculation after stent placement.
After placement of the IUC, continence is maintained
in the majority of the patients. The common causes of in-
continence are slipping of the IUC distal to the verumon-
tanum and urge incontinence secondary to urinary tract
infection. Repositioning of the IUC under cystoscopic
control and treatment of infection restores continence in
these patients. The use ofan appropriate sized IUC (length
of IUC) as determined by cystourethroscopy reduced the
incidence of distal migration and hence incontinence in
our study.
It is important to conduct long-term follow-up of these
patients with urine culture and plain frontal supine X-ray
of the abdomen so that significant urinary tract infections
and other complications such as major encrustation of the
IUC can be detected and managed early.
Recently with newer technology developed in the bil-
iary tract and blood vessels, there are reports advocatingIUC FOR URINARY RETENTION IN BPH 117
the use ofpermanent prostatic stents such as titanium stents
and the UroLume stent (8-11). Although the success rates
achieved are satisfactory, these stents are expensive and
long-term results are not yet known.
CONCLUSIONS
The intraurethral catheter is a simple device that alleviates
urinary retention in patients with benign prostatic hyper-
trophy. The IUC can be placed under local anesthesia with
ease, has minimal morbidity, and is relatively free of com-
plications. The majority of the patients have a satisfactory
voiding pattern andremain fully continent. By obviating the
need for a periurethral catheter, the IUC allows the patient
to discharge his day-to-day activities comfortably, as well
as resume normal coital habits. Thus, the IUC is a viable al-
ternative to an indwelling urethral catheter in patients with
urinary retention caused by BPH, who are unfit for surgery
due to medical illness or are awaiting definitive surgery.
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